Glucagon-Like Peptide-2 Receptor
"Glucagon-Like Peptide-2 Receptor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A receptor for GLUCAGON-LIKE PEPTIDE 2 (GLP-2) that is expressed on the surface of intestinal cells as well as neural cells. GLP-2 and other peptides act through GLP-2R to regulate cellular responses to BLOOD GLUCOSE, INFLAMMATION, and FOOD INTAKE.
| Descriptor ID |
D000067758
|
| MeSH Number(s) |
D12.776.543.750.695.021.600 D12.776.543.750.750.360.100.600
|
| Concept/Terms |
Glucagon-Like Peptide-2 Receptor- Glucagon-Like Peptide-2 Receptor
- Peptide-2 Receptor, Glucagon-Like
- Receptor, Glucagon-Like Peptide-2
- GLP-2 Receptor
- GLP 2 Receptor
- Receptor, GLP-2
- GLP2R Protein
- Protein, GLP2R
- Glucagon-Like Peptide 2 Receptor
- Glucagon Like Peptide 2 Receptor
- GLP-2R Receptor
- GLP 2R Receptor
- Receptor, GLP-2R
|
Below are MeSH descriptors whose meaning is more general than "Glucagon-Like Peptide-2 Receptor".
Below are MeSH descriptors whose meaning is more specific than "Glucagon-Like Peptide-2 Receptor".
This graph shows the total number of publications written about "Glucagon-Like Peptide-2 Receptor" by people in this website by year, and whether "Glucagon-Like Peptide-2 Receptor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 2 | 2 |
| 2020 | 0 | 1 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glucagon-Like Peptide-2 Receptor" by people in Profiles.
-
Kelly MS, Scopelliti EM, Goodson KE, Lo CMA, Nguyen HX, Simon B. Real-world evaluation of the effects of tirzepatide in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2024 12; 26(12):5661-5668.
-
Jabbour S, Paik JS, Aleppo G, Sharma P, Gomez Valderas E, Benneyworth BD. Switching to Tirzepatide 5?mg From Glucagon-Like Peptide-1 Receptor Agonists: Clinical Expectations in the First 12 Weeks of Treatment. Endocr Pract. 2024 Aug; 30(8):701-709.
-
Zhang T, Ahn K, Emerick B, Modarai SR, Opdenaker LM, Palazzo J, Schleiniger G, Fields JZ, Boman BM. APC mutations in human colon lead to decreased neuroendocrine maturation of ALDH+ stem cells that alters GLP-2 and SST feedback signaling: Clue to a link between WNT and retinoic acid signalling in colon cancer development. PLoS One. 2020; 15(10):e0239601.
-
Pablo Frias J, Lorenz M, Roberts M, Dex T, Schmider W, Hurst W, Skolnik N. Impact of lixisenatide dose range on clinical outcomes with fixed-ratio combination iGlarLixi in patients with type 2 diabetes. Curr Med Res Opin. 2019 04; 35(4):689-695.
-
Handelsman Y, Chovanes C, Dex T, Giorgino F, Skolnik N, Souhami E, Stager W, Niemoeller E, Frias JP. Efficacy and safety of insulin glargine/lixisenatide (iGlarLixi) fixed-ratio combination in older adults with type 2 diabetes. J Diabetes Complications. 2019 03; 33(3):236-242.
-
Skolnik N, Dupree RS, Johnson EL. iGlarLixi, a titratable once-daily fixed-ratio combination of basal insulin and lixisenatide for intensifying type 2 diabetes management for patients inadequately controlled on basal insulin with or without oral agents. Curr Med Res Opin. 2017 12; 33(12):2187-2194.